MLive hosting virtual seminar on cannabis industry on Thursday, March 11 mlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mlive.com Daily Mail and Mail on Sunday newspapers.
Release date
The makers did not announce a release date yet, however, reports suggest that it is set to premiere later this year on the Paramount Network.
A scene from the Paramount series Yellowstone (IMDb)
Plot
The upcoming series will follow the Dutton Family and their journey to find a better future for themselves. The official synopsis reads: “The show follows the Dutton family as they embark on a journey west through the Great Plains toward the last bastion of untamed America. It is a stark retelling of Western expansion, and an intense study of one family fleeing poverty to seek a better future in America’s promised land: Montana.”
Premium Content
Subscriber only
MOUNTAIN bike riders will take the trail later this month in honour of a member responsible for making Rowallan Park a notable destination.
MAD MTB Club founding member Jeff Rafferty was well known throughout the cycling community as a great bloke always up for a chat and providing advice and support for those who needed it.
Back in 2017, he was diagnosed with an aggressive brain cancer and he passed away in September 2019.
His love and passion of the sport inspired many to start riding and resulted in the MAD Club named an annual event in his honour called Raff’s Race.
Summary
Digital displays are ubiquitous in modern daily life. In many areas, such displays have replaced, or are in the process of replacing, conventional items such hard-copy books, analogue watches and car dashboard gauges. Similarly, many clinical vision tests are increasingly being presented on a range of modern visual displays ranging from LCD monitors to OLED displays for use in the home and clinical settings; a move away from antiquated (but still regularly used) non-digital systems. Measurements obtained from these devices are relied upon by clinicians to make decisions about patient wellbeing and treatment, and therefore need to be fit-for-purpose to meet the challenges of modern-day clinical practice. Despite the positive move to more modern platforms, it is still imperative that legacy measures, often collected over decades, can be incorporated into the determination of disease stability or otherwise. Thus, there is a need to ensure that the benefits of novel platforms ar
Summary
The prevalence of type 2 diabetes has risen dramatically during recent decades and there is an urgent need to develop new approaches for therapeutic treatment that provide a combination of benefits, with fewer side effects and better patient outcomes. When diabetes is not managed, it can lead to serious complications including cardiovascular disease (CVD), stroke, blindness, kidney disease and premature mortality. CVD is a major cause of death and disability in diabetes, accounting for 52% of fatalities in those with type 2 diabetes.
New treatments are necessary due to the increasing prevalence of diabetes and its complications. In recent years, therapies that target the actions of glucagon-like peptide-1 (GLP-1) which stimulate insulin secretion through activation of beta cell G protein-coupled receptors (GPCRs) have been successful. This has resulted in substantial interest in targeting other islet GPCRs for diabetic therapies [1-3]. GPCRs are a superfamily of transmembra